An innovative approach to address unmet medical need in cancer therapy

Lead development candidate CB-103 is a small molecule that has been selected as drug development candidate for preclinical and clinical development as targeted oncology therapy.

cellestia-biotech-hero

An innovative approach to address unmet medical need in cancer therapy

Lead development candidate CB-103 is a small molecule that has been selected as drug development candidate for preclinical and clinical development as targeted oncology therapy.